MNOV — MEDICINOVA INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1226616 ·
Last close
$1.53
Market Cap
$75.31M
52W High
$1.55
52W Low
$1.22
ADV30
39,915
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 186,984 | 16,883 | -2,835,806 | -2,586,258 | 42,704,854 | 27,329,415 | 3,297,620 |
| Dec 2025 | 151,739 | 4,754 | -3,092,402 | -2,802,279 | 45,603,109 | 30,806,477 | 4,016,428 |
| Sep 2025 | 123,319 | 8,047 | -3,380,998 | -3,050,373 | 47,578,388 | 32,562,612 | 3,613,632 |
| Jun 2025 | 134,599 | 18,250 | -3,607,092 | -3,281,185 | 49,823,875 | 34,259,637 | 2,967,006 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,496,613
Investing CF
$-13,724
Financing CF
—
CapEx
$-10,825
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-441,335,457
Inventory
—
Receivables
$245,100
ST Investments
—
EBIT TTM
$-12,916,298
Pretax Income TTM
$-11,714,101
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$920,481
EBITDA
$-11,831,257
Free Cash Flow
$-5,738,905
Enterprise Value
$50,009,624
Total Cash
$25,415,920
Total Debt
$117,038
Shares Out
49,221,246
Trailing EPS
$-0.21
Book Value
$0.76
ROE
-25.6%
ROA
-16.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 409,657 | -13,283,002 | -11,997,957 | 45,603,109 | 4,016,428 | — | -9,810,061 |
| Dec 2024 | 0 | -12,675,331 | -11,049,549 | 55,875,926 | 3,372,375 | — | -10,642,964 |
| Dec 2023 | 1,000,000 | -9,900,265 | -8,571,516 | 66,269,977 | 3,891,553 | — | -7,431,038 |
| Dec 2022 | 0 | -14,628,649 | -14,069,083 | 74,154,905 | 3,912,870 | — | -12,911,563 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.45
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.56 · call volume: 50 · put volume: 0
Expected Move to 2026-09-18:
±$1.55
(99.36%) —
implied range
$0.01 –
$3.11
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANVS | Annovis Bio, Inc. | $74.56M | $1.75 | — |
| ELTX | Elicio Therapeutics, Inc. | $78.32M | $2.98 | — |
| OSTX | OS Therapies Inc | $72.03M | $1.55 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $79.32M | $0.75 | — |
| ZOMDF | Zomedica Corp. | $80.06M | $0.08 | — |
News headlines (Yahoo Finance, 1h cache)
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
2026-07-15 12:00 · Yahoo
MediciNova CEO Provides Shareholder Update
2026-06-30 12:00 · Yahoo
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
2026-06-08 12:00 · Yahoo
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-05-26 23:00 · Yahoo
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026-04-27 23:00 · Yahoo
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other
2026-06-08 17:00 · Yahoo
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 22:50 · Yahoo
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
2026-08-12 22:15 · Yahoo
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 23:10 · Yahoo
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
2026-05-16 12:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.